Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone long-term safety extension in pediatric chronic kidney disease with proteinuria
2021-002905-89Phase 3Active
- Sponsor
- Bayer
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of finerenone in chronic kidney disease (CKD), sponsored by Bayer. Primary endpoint: Number of participants with treatment emergent adverse events. Started Jul 2022; status: active.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-002905-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002905-89.